# Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

> **NCT02607956** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 657 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** DTG
- **DRUG:** F/TAF
- **DRUG:** B/F/TAF
- **DRUG:** DTG Placebo
- **DRUG:** F/TAF Placebo
- **DRUG:** B/F/TAF Placebo

## Key facts

- **NCT ID:** NCT02607956
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-11
- **Primary completion:** 2017-05-12
- **Final completion:** 2021-07-05
- **Target enrollment:** 657 (ACTUAL)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607956, "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02607956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*